Physician profile
Daryl Sherrod
NPI 1851354740
$3,758.58
in general payments reported to CMS, 2019-2025
21 companies · $605 in 2025
The $605 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $671 · 2021: $870 · 2022: $840 · 2023: $84.77 · 2024: $345 · 2025: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $901.70 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $562.91 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $559.79 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $310.36 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $257.73 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Pfizer INC. | $198.18 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.22 | 2019-2022 | |
| Abbvie INC. | $178.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $140.09 | 2019-2020 | |
| Dexcom, INC. | $72.21 | 2024-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $67.58 | 2022-2023 | Seglentis, Livalo |
| Allergan, INC. | $61.94 | 2020 | |
| Inogen, INC. | $50.49 | 2022 | |
| Exact Sciences Corporation | $40.81 | 2024-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $37.58 | 2022-2024 | Shingrix |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.13 | 2022-2025 | Eterna |
| Amgen INC. | $27.77 | 2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $23.50 | 2019 | |
| Boston Scientific Corporation | $22.06 | 2024 | Wavewriter Alpha Prime 16 |
| Actelion Pharmaceuticals US, INC. | $20.66 | 2025 | Uptravi, Opsumit |
| Teva Pharmaceuticals USA, INC. | $14.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Sherrod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.